MRI staging using gadodiamide for soft-tissue tumors of the head and neck region. Results from a phase II trial and a 5-year clinical follow-up

Ekholm, S.E; Björk-Eriksson, T; Western, A; Nellström, H; Jonsson, E; Johansson, A; Lönn, L; Mercke, C; Tollesson, P.O

« Previous Next »European Journal of Radiology
Volume 39, Issue 3 , Pages 168-175, September 2001

MRI staging using gadodiamide for soft-tissue tumors of the head and neck region. Results from a phase II trial and a 5-year clinical follow-up

S.E Ekholm
- Department of Diagnostic Radiology, Sahlgrenska University Hospital, MR Center, P.O. Box 75014, SE-40036 Göteborg, Sweden
- Corresponding author. Tel.: +46-31-604-098; fax: +46-31-411-673
T Björk-Eriksson
- Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden
A Western
- Nycomed Imaging AS, Clinical R&D, Oslo, Norway
H Nellström
- Department of Diagnostic Radiology, Sahlgrenska University Hospital, MR Center, P.O. Box 75014, SE-40036 Göteborg, Sweden
E Jonsson
- Nycomed AB, Stockholm, Sweden
A Johansson
- Department of Diagnostic Radiology, Sahlgrenska University Hospital, MR Center, P.O. Box 75014, SE-40036 Göteborg, Sweden
L Lönn
- Department of Diagnostic Radiology, Sahlgrenska University Hospital, MR Center, P.O. Box 75014, SE-40036 Göteborg, Sweden
C Mercke
- Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden
P.O Tollesson
- Department of Diagnostic Radiology, Sahlgrenska University Hospital, MR Center, P.O. Box 75014, SE-40036 Göteborg, Sweden

Received 3 November 1998; received in revised form 23 March 1999; accepted 24 March 1999.

Abstract

In order to document the safety, tolerability and efficacy of gadodiamide outside CNS, an open, non-drug comparative study was performed in patients with tumors of the head and neck region. Fifty adult patients were included and 48 patients received the contrast medium. The examinations were performed on a 1.5 T imager using transverse, non-enhanced T1- and PD-/T2-weighted conventional spin-echo sequences, followed by a contrast-enhanced transverse T1-weighted sequence. Post-contrast images provided more diagnostic information compared to unenhanced images in 33 of 48 patients (69%). This information was of significant help in four and of moderate help in 14 cases. Post-contrast images compared to non-enhanced T1-weighted showed improvement in lesion delineation for 29 of the 43 patients where a lesion was observed. Only in two patients was the diagnostic information lower post-contrast. A comparison between all pre-contrast images versus contrast medium enhanced showed post-contrast images to give more diagnostic information in 14 and less in nine patients. No patient experienced discomfort in relation to gadodiamide injection. Only one adverse event occurred which was described as thirst, being of moderate intensity. The 5-year clinical outcome was analyzed and compared with the pre-operative staging. The case-books of all patients were reviewed and in 44 patients all information could be found. Of those, 18 were still alive, one with active disease (AAD) and 17 with no evidence of disease (NED). Two of those four patients, where information was incomplete, showed NED and two had died. This trial showed that contrast-enhancement using gadodiamide for evaluation of soft tissue tumors in the head and neck region was safe and provided statistically significant more diagnostic information compared with unenhanced images. MRI, when compared with palpation/inspection, changed tumor staging in ≈30% of all cases.

Keywords: Gadodiamide, Tumour, Head and neck, MRI, 5-year survival